Kasvu Therapeutics

Rapid-acting, non-hallucinogenic neuroplasticity enhancers for major depression and other brain disorders. Lead candidate KTX-0141 targets the TrkB receptor without binding serotonin receptors; first human trials expected in summer 2027. Univ. of Helsinki spin-out (2023) built on Eero Castrén's neuroplasticity research.

The row

Sector

Therapeutics & Diagnostics

Stage

Pre-revenue — No sales yet

Location

Helsinki

Founded

2023

Research origin

Univ. of Helsinki

Business ID

3367901-3 · Finnish trade register

Funding

€30M round (9/2026, Hadean Ventures lead; Tesi, Innovestor, Nordic Science Investments, Finnish Drug Discovery Center, Stephen Industries, University of Helsinki Funds), the largest raised by a Finnish preclinical-stage drug developer (Univ. of Helsinki, 24.9.2026); ~€6M earlier (2024)

Rounds

2026 · EUR 30M · equity Hadean Ventures lead; Tesi, Innovestor, NSI, FDDC, Stephen Industries, Univ. of Helsinki Funds

Links

Where this sits on the map

Kasvu Therapeutics is one of 33 companies in Therapeutics & Diagnostics. The others:

How this row was decided

Every row on this map is checked by hand against the trade register and the company's own material, and placed in the sector that best describes its business or its technology. Service firms and consultancies are left out, however advanced the technology they work with — the test is where the revenue comes from. Only funding figures the company or its investor has published are shown. The full rules are on the landscape ↗